Peptidoglycan preparation from Bifidobacterium longum CCM 7952 mitigates allergic airway inflammation in a MyD88-dependent manner
Year: 2026
Type: article
Abstract: Intranasal administration of heat-inactivated Bifidobacterium longum CCM7952 (Bl7952) alleviates allergic airway inflammation (AAI); however, the specific cell-wall components responsible for this anti-allergic effect, as well as the underlying immunological mechanism, remain unknown. In this study, the anti-allergic and immunomodulatory properties of Bl7952 cell-wall components were investigated in female BALB/c, C57BL/6, NOD2 −/− , and MyD88 −/− mice using a murine model of AAI. Four hours before each allergen (ovalbumin) application, isolated Bl7952 surface components, including slime and cell wall-derived polysaccharides, surface proteins, or a peptidoglycan preparation, were administered intranasally. Among these components, only the peptidoglycan preparation significantly down-regulated the Th2-associated immune response and eosinophil infiltration into the lungs. This effect was largely dependent on MyD88 adapter protein and independent of NOD2 receptor signaling. Furthermore, the Bl7952-derived peptidoglycan preparation altered the frequencies of antigen-presenting and T cells in the lungs of naïve mice. Thus, the peptidoglycan preparation from Bl7952 exerts prophylactic anti-allergic effects, underscoring its potential as an immunomodulator for preventing AAI.
Source: Scientific Reports
Authors: Tereza Hornikova, Sabina Gorska, Sudhanshu Shekhar, Katarzyna Pacyga-Prus, Marcelina Pyclik, Katarzyna Leszczyńska-Nowak, Tereza Novotna, Anna Michl, Umesh Kumar Gautam, Michael Thaler, Viktor Cerny, Barbora Valaskova, Aleksandra Inic-Kanada, Irma Schabussova, Martin Schwarzer, Dagmar Srutkova
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7235676848
